Monthey, Valais, Switzerland – April 4th, 2024 – Orio Therapeutics, a biotechnology company at the forefront of protein engineering for regenerative medicine, today announced the successful closure of a CHF 500,000 pre-seed funding round. This investment, secured from angel investors, will propel the company’s ambitious goal of revolutionizing treatment approaches for patients suffering from debilitating conditions.

Orio Therapeutics will utilize the funding to initiate crucial pre-clinical studies for its lead program: a groundbreaking cardioprotective drug designed for heart attack patients. This novel therapy aims to prevent the extensive and often irreversible damage that commonly occurs following an acute myocardial infarction.

“We are deeply grateful for the confidence our investors have placed in our team and our cutting-edge approach,” said Dr. Ziad Julier, CEO of Orio Therapeutics. “Current treatments for heart attack patients often fall short of preventing long-term complications. With this funding, we’re one step closer to providing a solution that truly addresses this significant unmet need.”

About Orio Therapeutics Orio Therapeutics is a biotechnology company dedicated to unlocking the power of protein engineering and targeted drug delivery for the creation of next-generation regenerative medicines. The company’s innovative platform addresses fundamental limitations in current treatments, promising increased effectiveness and reduced side effects across various therapeutic areas. Orio Therapeutics operates with headquarters at the BioArk Technological Site in Monthey, Valais, Switzerland, and a secondary location at Monash University in Melbourne, Australia.